EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unveiling the domain-specific and RAS isoform-specific details of BRAF kinase regulation

Tarah Elizabeth Trebino iD, Borna Markusic iD, Haihan Nan, Shrhea Banerjee iD, Zhihong Wang iD

eLife · 2023

DOI: 10.7554/elife.88836 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Tarah Elizabeth Trebino und 4 weiteren Autor:innen. Beteiligte Einrichtung: Rowan University, Glassboro, United States. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Biological Assay. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, WW Smith Charitable Trust, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRAF is a key member in the MAPK signaling pathway essential for cell growth, proliferation, and differentiation. Mutant BRAF is often the underlying cause of various types of cancer and mutant RAS, the upstream regulator of BRAF, is a driver of up to one-third of all cancers. BRAF interacts with RAS and undergoes a conformational change from an inactive, autoinhibited monomer to an active dimer, which propagates downstream signaling. Because of BRAF’s complex regulation mechanism, the exact order and magnitude of its activation steps have yet to be confirmed experimentally. By studying the inter- and intramolecular interactions of BRAF, we unveil the domain-specific and isoform-specific details of BRAF regulation through pulldown assays, open surface plasmon resonance (OpenSPR), and hydrogen-deuterium exchange mass spectrometry (HDX-MS). We demonstrate that the BRAF specific region (BSR) and cysteine rich domain (CRD) play a crucial role in regulating the activation of BRAF in a RAS isoform-specific manner. Moreover, we quantified the binding affinities between BRAF N-terminal and kinase domains (KD) to reveal their individual roles in autoinhibition. Our findings also indicate that oncogenic BRAF-KD D594G mutant has a lower affinity for the N-terminal domains, implicating that pathogenic BRAF acts through decreased propensity for autoinhibition. Collectively, our study provides valuable insight into the activation mechanism of BRAF kinase to guide the development of new therapeutic strategies for cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafBiological AssayCell CycleCell DifferentiationProtein Isoforms

Stichwörter der Autor:innen

E. coliMAPK signalingRAF kinaseRASbiochemistrychemical biology

Substanzen

Proto-Oncogene Proteins B-rafProtein Isoforms

Autor:innen und Institutionen

  • Rowan University, Glassboro, United States.
  • Max Planck Institute of Biophysics, Frankfurt am Main, Germany.
  • School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China.

ORCID-Profile: Tarah Elizabeth Trebino, Borna Markusic, Shrhea Banerjee, Zhihong Wang

Förderung

  • NIGMS NIH HHS
  • WW Smith Charitable Trust
  • National Institute of General Medical Sciences

Zitieren

APA

Trebino, T. E., Markusic, B., Nan, H., Banerjee, S., & Wang, Z. (2023). Unveiling the domain-specific and RAS isoform-specific details of BRAF kinase regulation. eLife. https://doi.org/10.7554/elife.88836

Vancouver

Trebino TE, Markusic B, Nan H, Banerjee S, Wang Z. Unveiling the domain-specific and RAS isoform-specific details of BRAF kinase regulation. eLife. 2023. doi:10.7554/elife.88836

BibTeX
@article{Trebino2023,
  author = {Trebino, Tarah Elizabeth and Markusic, Borna and Nan, Haihan and Banerjee, Shrhea and Wang, Zhihong},
  title = {Unveiling the domain-specific and RAS isoform-specific details of BRAF kinase regulation},
  journal = {eLife},
  year = {2023},
  doi = {10.7554/elife.88836}
}
Kostenlos starten →